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Medical Instrumentation—Review
AB STRACT Cutting-edge technologies in optical molecular 
imaging have ushered in new frontiers in cancer research, 
clinical translation, and medical practice, as evidenced 
by recent advances in optical multimodality imaging, 
Cerenkov luminescence imaging (CLI), and optical image-
guided surgeries. New abilities allow in vivo cancer imaging 
with sensitivity and accuracy that are unprecedented in 
conventional imaging approaches. The visualization of cellular 
and molecular behaviors and events within tumors in living 
subjects is improving our deeper understanding of tumors 
at a systems level. These advances are being rapidly used 
to acquire tumor-to-tumor molecular heterogeneity, both 
dynamically and quantitatively, as well as to achieve more 
effective therapeutic interventions with the assistance of 
real-time imaging. In the era of molecular imaging, optical 
technologies hold great promise to facilitate the development 
of highly sensitive cancer diagnoses as well as personalized 
patient treatment—one of the ultimate goals of precision 
medicine. 
KEYWORDS optical molecular imaging, multimodality 
molecular imaging, optical multimodality tomography, 
Ce renkov luminescence imaging, intraoperative image-guided 
surgery
1 Introduction
Imaging has become an un precedentedly powerful tool in 
preclinical cancer research and clinical practice. In the past 
15 years, there has been a signiﬁ cant increase in the number 
of imaging technologies and their applications in the ﬁ eld of 
oncology [1–4], but perhaps the biggest breakthroughs are in 
the new developments in optical molecular imaging (OMI). 
With recent advances in optical multimodality imaging, Ce-
renkov luminescence imaging (CLI), and intraoperative opti-
cal image-guided surgery, the sensitivity and accuracy of tu-
mor diagnoses and therapeutic interventions have moved to 
a whole new level. Researchers and clinicians are now on the 
verge of being able to address some of the important ques-
tions in oncology that were once impossible to conclusively 
answer. How do we shift from conventional in vitro assay-
based ﬁ ndings to non-invasive in vivo imaging-based detec-
tion? Is it possible to obtain accurate and quantitative biologi-
cal information (e.g., the receptor density in tumor tissues) on 
a three-dimensional (3D) cellular or sub-cellular level? How 
can we better delineate tumor boundaries and guide tumor 
resection? Can we exceed the sensitivity limitation of conven-
tional imaging methods for effective small tumor foci detec-
tion both preoperatively and intraoperatively? How do we 
translate preclinical OMI into clinical applications for better 
tumor treatment outcomes?
In this article, we highlight some recent advances of OMI 
in three categories: optical multimodality imaging, CLI, and 
optical image-guided surgery. We review cutting-edge opti-
cal imaging instruments, the development of optical tomo-
graphic imaging models and reconstruction algorithms, and 
promising optical imaging strategies with smart utilization 
of multiple molecular probes in both breadth and depth. We 
also demonstrate speciﬁ c applications and state-of-the-art in 
vivo imaging examples of OMI in biomedical research and 
recent clinical translations. 
2 In vivo optical multimodality molecular imaging
Different imaging modalities have their inherent advantages 
and disadvantages, and they are complementary. For exam-
ple, radionuclide imaging has a superb sensitivity to molecu-
lar targets but a limited spatial resolution, whereas computed 
tomography (CT) and magnetic resonance imaging (MRI) 
can offer good spatial resolution but suffer from low sensitiv-
ity in detecting molecular events [5]. Planar optical imaging 
that adopts photographic principles is the simplest technique 
for capturing visible and/or near-infrared (NIR) light emit-
ting from optical reporter molecules in vivo [6–8]. This planar 
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technique can offer good superficial 
resolution (the resolution of an imaging 
subject surface), high sensitivity, and 
high-throughput imaging ability, and 
it is technically easy to implement pre-
clinically [9]. However, it also has two 
major limitations. The ﬁ rst limitation is 
the difﬁ culty in quantiﬁ cation of the in 
vivo distribution of optical probes due 
to the nonlinear relationship in spatial 
position and signal strength between 
the detected surface flux and the light 
source [10]. The second is the relatively 
shallow imaging depth due to the sig-
niﬁ cant light scattering and absorption 
inside the tissue and organs of imaged 
animals [11]. These features result in 
the application of this approach pri-
marily to qualitative superficial obser-
vation. Although various efforts have 
been made to develop different algo-
rithms for tomographic reconstruction 
solely using planar optical images, the 
process inevitably involves erroneous 
interpretation of the data collected un-
less the nonlinear effects are explicitly 
corrected or accounted for [9]. There-
fore, combining planar optical imaging 
with other modalities is recommended 
in order to compensate for these limita-
tions while building on its strengths to 
capitalize on its great potential [12].
2.1 From 2D qualitative to 3D quantitative 
imaging
Tomographic reconstruction of the bio-
distribution of optical molecular probes 
can be traced back to the early 1990s. 
The first theoretical frameworks were 
proposed as a way to spatially resolve 
intrinsic tissue contrast in the context of 
studying hemodynamics or organelle 
concentration [13–16]. Visible and NIR 
photons (from 650 nm to 950 nm) are 
highly scattered in tissue and start to 
diffuse within a millimeter of propaga-
tion [17]. However, a portion of the light 
can still penetrate several centimeters 
and reach a small-animal skin surface 
because of the low photon absorption in 
this spectral window [18, 19], which is 
known as the ﬁ rst NIR window (NIR-I) 
[20, 21]. At wavelengths shorter than 
650 nm, there is an increased absorp-
tion by blood (oxygenated and deoxy-
genated) and skin, whereas at wave-
lengths longer than 950 nm, water and 
lipids demonstrate stronger absorption. 
In recent optical multimodality tomography (OMT), the diffuse light patterns are 
collected from a small animal surface at one or multiple angles using photodetector 
sets or various charge-coupled-device (CCD) cameras. Meanwhile, the anatomical 
structure of the animal is acquired using CT or MRI (Figure 1) as one of the a priori 
sets of information for helping optical reconstruction. Based on the types of optical 
molecular probe applied, this 3D non-invasive whole-body small-animal imaging 
technology is subdivided into three categories: ﬂ uorescence molecular tomography 
(FMT, employing fluorescent probes and external illumination sources) [22, 23], 
bioluminescence tomography (BLT, employing reporter genes, luciferin substrates, 
an d no external illumination sources) [24, 25], and Cerenkov luminescence tomog-
raphy (CLT, employing radioactive probes and no external illumination sources) 
[26, 27]. With the presence of the extra dimension, the combination of sufficient 
imaging information from different modalities, and appropriate optical molecu-
lar probes with specificity to cellular and sub-cellular processes, OMT is able to 
overcome the ﬁ rst limitation of the conventional planar optical imaging technique 
mentioned earlier, and offer more accurate and robust quantitative imaging on a 
cellular and molecular level. 
The hardware setup of these multimodality imaging methods may vary in dif-
ferent biomedical applications or when prepared by different research groups (Fig-
ure 1). Examples include the hybrid optical-CT imaging system shown in Figure 1(a) 
and (b), the hybrid optical-MRI system in Figure 1(c)–(e), and the triple-modality 
optical-CT-MRI system shown in Figure 1(f) and (g). However, there are two generic 
factors that have signiﬁ cant inﬂ uence on tomographic performance. First, it is cru-
cial to develop appropriate mathematical imaging models describing photon propa-
gation in tissues—an issue that is known as the forward problem; and second, it is 
equally important to develop sophisticated algorithms for tomographic reconstruc-
Figure 1. Examples of different OMT systems. (a) The diagram and (b) internal structure of the hybrid 
FMT-CT system developed by the Vasilis Ntziachristos group, reproduced from Refs. [28, 29]; the optical 
and CT subsystems are perpendicular to each other, and the mouse lies in the center of the rotating gantry 
during imaging acquisition. (c)–(e) The FMT-MRI system developed by the Brian Pogue group, reproduced 
from Ref. [30]. (c) A diagram of the MRI-coupled 16-channel optical system for ﬂ uorescence tomography. 
(d) The mouse with MRI coil and ﬁ ber bundles lies inside a clinical 3T MRI system. (e) The optical system is 
inside the MRI control room. (f) & (g) The triple-modality optical-CT-MRI system developed by the Jie Tian 
group. (f) The system design diagram shows that the optical and CT subsystems are installed on the rotating 
gantry, whereas the cubic MRI subsystem (1 T permanent magnet) is installed in the middle of the gantry 
and the small animal transmit unit. Since the system is still in development, the ﬁ nal position of the MRI 
subsystem may differ from the original design (g). 
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tion—an issue that is known as the inverse problem [9, 10]. 
Typical forward problems proposed for OMT are based on 
numerical or analytical solutions of the diffusion equation 
with the assumption that the imaging subjects are homoge-
neous in optical properties [31–33]. To further improve the 
accuracy, different forward models based on approximate 
solutions to the radiative transport equation, on diffusion 
equation solutions merged with radiosity principles, or on 
higher-order spherical harmonic approximations were also 
proposed for different tissue and organs where optical prop-
erties were assumed to be heterogeneous inside living small 
animals [10, 34, 35]. There is an evolution of the optical imag-
ing model toward better accuracy with acceptable increase of 
the computational cost for in vivo applications. 
Due to high photon scattering in tissues, the system matrix 
of OMT is ill-conditioned and the inverse reconstruction is 
ill-posed [36]. In contrast to single modality optical tomogra-
phy, OMT can utilize prior information or guidance obtained 
from other imaging modalities in order to minimize these 
problems. Furthermore, various regularization methods, 
such as Tikhonov regularization [37], sparsity regularization 
[38], total variation regularization [39], and reweighted L2 and 
L1 regularizations [40, 41], can be employed to achieve compu-
tationally fast and robust reconstruction. These methods can 
be used with fast analytical solvers or numerical solutions in 
order to further accelerate the reconstruction speed [42, 43]. 
Overall, there is a consistent demand for faster and more ro-
bust inverse algorithms, as the acquired data sets increase in 
size due to the application of more complicated multimodal-
ity imaging systems.
With the rapid development of hardware systems, optical 
imaging models, and tomographic reconstruction algorithms, 
OMT has become more and more practical and easy to imple-
ment. In the last decade, there has been a significant shift 
from mathematical simulation or artiﬁ cial phantom studies 
to in vivo small-animal studies in the field of OMT. A wide 
range of unique biomedical applications in small-animal tu-
mor model imaging was investigated by several pioneering 
groups all over the world. Here, we summarize some of the 
most recent breakthrough studies in order to demonstrate the 
superiority of the hybrid FMT and BLT. As CLT is reviewed 
in more detail in Section 3, we do not introduce its in vivo ap-
plications in this section in order to avoid repetition.
The Vasilis Ntziachristos group has successfully achieved 
highly accurate hybrid FMT-CT performance on a subcutane-
ous 4T1 tumor mouse model, an Aga2 osteogenesis imperfec-
ta model, a Kra s lung cancer mouse model and a pancreatic 
ductal adenocarcinoma model, as shown in Figure 2(a) [28, 
29]. The in vivo imaging results were compared to single mod-
al FMT and CT, respectively, and were also validated against 
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Figure 2. The non-invasive in vivo application of OMT. (a) 3D reconstruction of a subcutaneous 4T1 tumor model, an Aga2 osteogenesis imperfecta model, and 
a Kras lung cancer model using the FMT-CT technique, reproduced from Ref. [28]. (b) A procedure for recovering binding potential using a dynamic dual-tracer 
FMT-MRI technique, reproduced from Ref. [44]. (c) Dynamic dual-tracer FMT-MRI imaging of gliomas in mice; the ﬁ rst two rows are the time series coronal images 
showing ﬂ uorescence activity of the targeted and untargeted tracers, and the bottom plot shows the time series of ﬂ uorescence activity of targeted (● solid lines) 
and untargeted (○ dotted lines) tracers in the tumors of all animals, clearly demonstrating two different proﬁ les; reproduced from Ref. [44]. Mouse liver reconstruction 
results of (d) a new designed anti-tumor drug or (e) saline-treated mice using the BLT-CT technique; the images demonstrate that the drug showed higher anti-tumor 
efﬁ cacy compared with the control saline-treatment group. Reproduced from Ref. [45].
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post-mortem planar fluorescence images of cryoslices and 
histology data. The study vividly demonstrated that OMT 
can provide much more accurate 3D information on tumor le-
sions than either stand-alone FMT or CT can achieve, or than 
can be obtained using the planar optical imaging method.
The Jing Bai group and the Brian Pogue group have sepa-
rately developed FMT-CT and FMT-MRI techniques for dy-
namic fluorescence molecular imaging, both of which are 
powerful new four-dimensional tools for cancer research. 
They are especially useful as better ways of studying recep-
tor-targeted drug delivery and cancer progression non-inva-
sively. These groups employed their OMT approaches and 
successfully reported the binding kinetics of different optical 
molecular probes in the blood pool and in tumor xenografts 
[46–49]. Furthermore, the Brian Pogue group applied this 
technique to image the uptake kinetics of two optical probes 
in U251 brain tumor mouse models simultaneously. One 
probe targeted the receptor of interest, and the other acted 
as a non-targeted reference. (See Figure 2(b) and (c) for more 
detail.) These dynamic data were then fit to a dual-tracer 
compartmental model in order to achieve accurate quantiﬁ ca-
tion of the receptor density available for binding therapeutic 
drugs in tumor tissues [44]. The Pogue group also applied 
a similar imaging technique with dual-optical probes for 
the accurate quantiﬁ cation of tumor burden in lymph nodes 
in breast cancer mouse models. This non-invasive imaging 
method reached an ultimate sensitivity of approximately 200 
cells in detecting breast cancer metastasis (potentially more 
sensitive than conventional lymph node biopsy) [50].
In contrast to the above studies, the Jie Tian group devel-
oped a BLT-CT technique that was sufﬁ cient for in vivo imag-
ing and applied it to evaluate the therapeutic interventions of 
new designed anti-tumor drugs [45, 51]. For in vivo planar bio-
luminescence imaging (BLI) or 3D BLT, biological entities (e.g., 
tumor cells, immune cells, bacteria, or genes) are tagged with 
a reporter gene that encodes one of a number of light-generat-
ing enzymes (luciferases). In the presence of oxygen and other 
factors (e.g., ATP, Mg), enzymes convert unique substrates 
(luciferin) into light [52–54]. The propagation of emitted pho-
tons in living animals can be simulated as a diffusion process 
that is similar to ﬂ uorescence photon propagation. However, 
it is more difﬁ cult to achieve practical in vivo imaging using 
BLT than using multimodality FMT approaches, because BLT 
does not use external illumination sources. Although this fea-
ture carries the major advantage of a high tumor-to-normal-
tissue contrast due to the absence of inherent background 
noise, the fewer source-detector pairs available complicate the 
tomographic problem mathematically.
By integrating multi-angle (from 0° to 360°) imaging with 
a priori information on much more accurately deﬁ ned tissue 
heterogeneity, the Jie Tian group improved the performance 
of the inverse problem of BLT [10]. Their recent studies dem-
onstrate that with well-developed reconstruction algorithms, 
the technique can provide accurate 3D information on or-
thotopic liver tumors, and the anti-tumor efficacy of newly 
developed therapeutic drugs or other interventions can be 
monitored quantitatively without sacriﬁ cing the tumor-bear-
ing mice, as shown in Figure 2(d) and (e) [45, 51].
2.2 Toward deeper imaging depth
In addition to all the technological developments and bio-
medical applications of OMT described above, other research 
groups are acquiring optical molecular images and images 
from other modalities using separate systems, and then com-
bining the information to obtain better sensitivity and accu-
racy. This optical multimodality molecular imaging strategy 
normally involves the application of multimodal molecular 
probes and avoids the difficulty of developing complicated 
hybrid imaging systems. Recent achievements even circum-
vented the second limitation of conventional planar optical 
imaging and achieved deeper imaging depth.
The Sanjiv S. Gambhir group designed a unique triple-
modality (MRI-photoac oustic-Raman) imaging nanoprobe 
[55]. Because of the better tissue-penetrating ability of pho-
toacoustic imaging (PAI) and the better spatial resolution of 
optical Raman imaging, this triple-modality imaging strat-
egy allowed for non-invasive accurate brain tumor delinea-
tion through an intact skull, shown in Figure 3(a) and (b), and 
even more accurate intraoperative image guidance (microm-
eter scale) for tumor resection, shown in Figure 3(c)–(e). With 
the group’s in-house-modified imaging systems, the probes 
were detectable with at least picomolar sensitivity in living 
mice. These impressive features of this optical multimodal-
ity approach hold great promise for enabling more accurate 
and sensitive brain tumor imaging and resection than ever 
before.
In Gambhir’s study, PAI is the key to overcoming the 
limitation in optical imaging depth. The reason why this 
emerging hybrid imaging technique achieves better tissue 
penetration than conventional fluorescence and biolumi-
nescence imaging is because of its unique utilization of the 
photoacoustic effect [56]. It employs a pulsed nanosecond-
long laser beam instead of a continuous wave to illuminate 
the targets of interest (biomolecules or molecular probes), 
causing a slightly localized heating and resulting in thermo-
elastic expansion. This transient thermoelastic tissue expan-
sion generates pressure waves with high frequency that can 
be detected by ultrasonic transducers [57]. Therefore, PAI 
combines the advantages of optical excitation and acoustic 
detection. Since an acoustic wave has a much lower scatter-
ing coefﬁ cient in biological tissue than light does, PAI offers 
imaging at a greater depth than conventional optical imaging 
methods, as shown in Figure 3(a) and (b), thereby ultrasoni-
cally breaking through the optical diffusion limit [58]. Recent 
advances in PAI have made it a powerful imaging tool in 
both biological and clinical applications. In recent years, the 
Lihong Wang group and the Vasilis Ntziachristos group have 
been developing various PAI instruments and extending the 
applications of such instruments, respectively [59, 60]. Their 
efforts are likely to accelerate OMI from preclinical studies 
toward clinical translations in cancer diagnoses (e.g., the di-
agnosis of breast carcinoma and skin neoplasm). 
In addition to PAI, techniques using the second NIR win-
dow (NIR-II, 1000–1400 nm) have also been developed in 
order to overcome the limitation in optical imaging depth. 
Compared with the ﬁ rst NIR window, NIR-II can offer deep 
penetration depth in tissues (reduced scattering effect) and 
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a higher signal-to-noise ratio (low tis-
sue auto-fluorescence) for fluorescence 
imaging [20]. However, the synthesis of 
biocompatible and bright NIR-II ﬂ uores-
cent probes and the application of suit-
able CCD cameras with high quantum 
efficiency in this longer wavelength 
window play critical roles for achieving 
practical in vivo NIR-II imaging. The 
Hongjie Dai group reported the use of 
biocompatible, bright  single-walled car-
bon nanotubes (SWNTs) as NIR-II im-
aging contrast agents for the imaging of 
blood velocity in both normal and isch-
emic femoral arteries [61]. In this study, 
an indium gallium arsenide (InGaAs) 
camera and a conventional silicon (Si) 
camera were applied for NIR-II and 
NIR-I imaging, respectively, in a hybrid 
optical imaging system, as shown in 
Figure 4(a). A thorough comparison of 
the imaging performances in the two 
NIR windows demonstrated the su-
periority of NIR-II in obtaining more 
information from deeper tissues, as 
shown in Figure 4(b) and (c). The group 
also performed imaging of mouse ar-
terial blood flow in deep tissue at the 
ultrafast video-rate of > 25 fps (frames 
per second), with a high quantum yield 
of synthesized polymers as ﬂ uorescent 
agents, as shown in Figure 4(d)–(f) [62]. 
Furthermore, Dai’s group has reported 
the non-invasive through-scalp and 
Figure 3. In vivo triple-modality detection of brain tumors and Raman-guided intraoperative surgery. (a) After injecting the triple-modality molecular probe, 2D 
images of all three modalities (MRI, photoacoustic, and Raman) demonstrated clear tumor visualization. (b) 3D-rendering of MR images with the tumor segmented 
(red; top); overlay of 3D photoacoustic images (green) over MRI (middle); and overlay of MRI segmented tumor and photoacoustic image (bottom). (c) A living 
tumor-bearing mouse underwent craniotomy under general anesthesia. Quarters of the tumor were then sequentially removed. (d) Intraoperative Raman imaging 
was performed after each resection step, until the entire tumor had been removed by visual inspection. After the gross removal of the tumor, several small Raman 
signal foci were found in the resection bed (outlined by the dashed white square). (e) Subsequent histological analysis of sections from these foci demonstrated an 
inﬁ ltrative pattern of the tumor in this location, forming ﬁ nger-like protrusions extending into the surrounding brain tissue. As shown in the Raman microscopy image (far 
right), a Raman signal was observed within these protrusions. Reproduced from Ref. [55].
Figure 4. (a) Schematic of the imaging setup for concurrent NIR-I and NIR-II photons using Si and InGaAs 
cameras. (b) NIR-I ﬂ uorescence images and (c) NIR-II ﬂ uorescence images of blood vessels in the mouse. 
(a)–(c) are reproduced from Ref. [61]. (d) Imaging local blood redistribution with pDA-PEG; a white-light 
image showing the mouse with ~ 5 h heat-induced inﬂ ammation in the right hind limb (left to the viewer). 
(e) & (f) NIR-II ﬂ uorescence images of the mouse at different times after inducing inﬂ ammation. (d)–(f) are 
reproduced from Ref. [62]. (g) In vivo mouse brain imaging with SWNT-IRDye800 in different NIR sub-
regions. (h) & (i) The same mouse head is imaged both in NIR-I (850–900 nm) and NIR-II (1300–1400 nm) 
regions. The inferior cerebral vein, the superior sagittal sinus, and the transverse sinus are labeled 1, 2, and 3, 
respectively in (i). (g)–(i) are reproduced from Ref. [63].
through-skull brain imaging of mouse cerebral vasculature, without using craniot-
omy or skull-thinning techniques, as shown in Figure 4(g)–(i) [63]. In this work, the 
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imaging depth was 2 mm deeper than in previous efforts and 
the imaging rate of 5.3 fps permitted the dynamic monitoring 
of blood perfusion in the cerebral vessels of the mouse brain.
Recent advances in optical multimodality molecular imag-
ing are embodied in every aspect of the technology, includ-
ing optical molecular probes, and especially in the nanoscale. 
An enormous development has occurred in the form of a 
variety of new nanomaterials that are modified for in vivo 
OMI, such as polymers [64, 65], liposomes, micelles [66], me-
tallic nanoparticles (gold, silver, titanium, and quantum-dot) 
[67–69], inorganic particles (up- and down-conversion) [70–72], 
and carbon structures (nanotubes and nanodiamonds) [73, 
74]. Many groups are dedicated to synthesizing molecular 
probes with better optical properties that are applicable for 
multi-targets as well as for multimodality imaging in order 
to enhance the overall sensitivity and accuracy of the imag-
ing performance. However, even though there have been 
significant achievements in preclinical applications with 
nanoprobes (e.g., ultrasensitive primary gastric tumor and 
lymphatic metastasis imaging [72], ultrasensitive multiplexed 
diagnostics [69], etc.), and the future of OMI-based nanotech-
nology seems promising, the progress of clinical translation 
in OMI-based nanotechnology has still been slower than 
expected over the last decade. Major concerns regarding 
the metabolic rate and toxicity of nanoscale imaging agents 
inside human systems are still preventing their application 
in clinical practice. To the best of our knowledge, Doxils, Ab-
raxanes, and Feridexs are the only three nanoscale imaging 
agents that have been approved by the Food and Drug Ad-
ministration (FDA) for clinical use. All three are composed 
of simple formulations without tumor specificity. However, 
the emergence of CLI and intraoperative ﬂ uorescence image-
guided surgery may facilitate the clinical translation of OMI 
with clinically approved radioactive probes and operating-
room-ﬁ tted imaging systems.
3 Cerenkov luminescence imaging (CLI)
Cerenkov luminescence (CL) is the light generated when 
charged particles—usually electrons or positrons emitted 
from radioisotopes upon radioactive decay—exceed the 
speed of light in a dielectric medium. As an emerging OMI 
technology, CLI was ﬁ rst reported much more recently than 
ﬂ uorescence and bioluminescence planar or tomographic im-
aging technologies. Compared with nuclear imaging, which 
also employs radioactive tracers, CLI has several advantages 
that are inherent in optical imaging: higher throughput, cost 
savings, and greater surface resolution [75]. Furthermore, a 
variety of tracers approved by the FDA enable clinical ap-
plications [76–79], giving CLI a unique inborn advantage in 
clinical translation. However, the low intensity of CL and 
its violet-blue-dominated spectrum limit its depth of tissue 
penetration. Hence, significant signal amplification and al-
ternative imaging techniques are required to enhance CLI 
sensitivity. 
CLI suffers from tissue depth-dependent signal weaken-
ing, strict restriction of background light, and a lack of addi-
tional information, compared with positron emission tomog-
raphy (PET). To enhance the intensity of CLI signals and to 
complement PET, radiopharmaceutical-excited fluorescence 
imaging (REFI) [80], secondary Cerenkov-induced fluores-
cence imaging (SCIFI) [75], Cerenkov radiance energy trans-
fer (CRET) [81–86], radioluminescence imaging (RLI) [87–91], 
radioisotope energy transfer (RET) [92], and enhanced CLI 
(ECLI) [93, 94] have been explored. 
Self-illuminating 64Cu-doped nanoparticles (NPs), such as 
gold nanocages [89], nanoclusters [84, 92], CdSe/ZnS [83, 93], 
and CuInS/ZnS QD [83], shift Cerenkov radiation toward 
longer wavelengths. Rare earth nanophosphors doped with 
Eu3+, Tb3+, Er3+, and Yb3+ enable inherent multimodality and 
increase the signal-to-noise ratio of optical imaging [87, 88, 90, 
92, 94]. Among these studies, the Jie Tian group utilized euro-
pium oxide nanoparticles and radioactive tracers in order to 
convert γ and Cerenkov radiation into signal-enhanced red 
emission [80]. This unique internal dual-radiation excitation 
mechanism combined the advantages of nuclear and OMI 
and provided non-invasive yet highly sensitive detection of 
tiny early-tumor lesions (Figure 5).
In 2010, Liu et al. demonstrated multispectral, deep-tissue, 
and potentially targeted imaging by the in vivo excitation of 
quantum dots contained in Matrigel pseudotumors using a 
radiotracer source [82]. The three quantum dots can be mul-
tiplexed using corresponding ﬁ lters in order to acquire infor-
mation for each channel. In 2013, Thorek et al. proposed SCI-
FI [75] as a new CL imaging strategy that enables activatable 
imaging via the biologically specific fluorescent conversion 
of Cerenkov radiance. The multiparameter imaging of tumor 
markers with a high signal-to-background ratio is shown by 
using HER2/neu-targeted 89Zr-DFO-trastuzumab to excite 
αvβ3-targeted cRGD-QD605. The SCIFI signal indicates the 
co-expression of HER2/neu and αvβ3 signatures of tumor 
cells. Matrix metallopeptidase-2 (MMP-2) enzymatic activity 
in vivo imaging is presented via gold nanoparticles (AuNPs) 
conjugated with carboxyﬂ uorescein (FAM)-labeled peptides. 
The peptide sequence IPVSLRSG can be cleaved speciﬁ cally 
in the microenvironment of an MMP-2 positive tumor. Specif-
ic cleavage of the peptide dissociates ﬂ uorescence-quenching 
AuNPs from FAM; hence, the SCIFI signal indicates MMP-
2 enzymatic activity in vivo, which correlates with the ex vivo 
quantitative Western blotting assay.
Since Robertson et al. first detected luminescent signals 
from positron-emitting radionuclides using Xenogen IVIS 
(IVIS 100 or 200, Caliper Life Sciences, Alameda, CA, USA) 
[95], CLI featured as a low-cost imaging technology among 
radionuclide imaging modalities. To break the limit on 
penetration depth due to the strong scattering of Cerenkov 
light and to increase the sensitivity of CLI, Kothapalli et al. 
proposed the transmittal of Cerenkov light through differ-
ent clinical endoscopes and conventional optical ﬁ bers. They 
constructed an optical endoscopy imaging system, shown in 
Figure 6(a), in which a CCD camera was uncoupled with a 6 
mm ﬁ ber-optic bundle, shown in Figure 6(b), and used their 
system to successfully detect as low as 1 μCi of radioactivity 
emitted from 18F-FDG, as shown in Figure 6(c) [96]. With the 
development of endoscopic CI, Liu et al. built an optical en-
doscopy imaging system [97], shown in Figure 7, using a CCD 
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camera (Turbo 640-Z; Stanford Photonics Inc., Palo Alto, CA, 
USA) coupled with an optical imaging ﬁ ber bundle that was 
108 mm long, shown in Figure 7(a). The distal end of the ﬁ ber, 
shown in Figure 7(b), was coupled with a micro-imaging lens 
(Cinegon, F/1.4, 12-mm focal length; Schneider, Rueil Mal-
maison, France).
Intraoperative surgical guiding systems based on CLI have 
been demonstrated by Holland et al. [98] and Thorek et al. [99]. 
Holland et al. targeted HER2/neu-positive expressed BT-474 
subcutaneous tumors with 89Zr-DFO-trastuzumab and per-
formed a dissection of the BT-474 tumor under the guidance 
of CLI. Thorek et al. demonstrated the utilization of CLI to 
aid in the resection of sentinel lymph nodes [99]. Liu et al. [97] 
demonstrated the feasibility of utilizing a Cerenkov lumines-
cence endoscopy (CLE) system to guide the resection of tu-
mor tissues with an in vivo tumor imaging study, depicted in 
Figure 7(c) and (d). With further improvements in sensitivity 
and spatial resolution, clinical applications of CLE systems 
may arise in the near future.
CLI and CLE acquire only superficial scattered and at-
tenuated CL; therefore, they lose more accuracy as the depth 
of the radiotracer source increases. In 2010, two groups of 
researchers developed Cerenkov luminescence tomography 
(CLT) systems independently. Li et al. [100] measured the 
Cerenkov optical luminescence with a commercial optical 
imaging system (Caliper IVIS 100) and acquired a micro-PET 
scan (micro-PET II scanner) for the validation of radiotracer 
distribution and a micro-CT scan (Inveon, Siemens Preclini-
cal Solutions) for anatomic reference. As shown in Figure 8, 
due to the placement of two side mirrors, the CCD camera 
simultaneously captured images of the emitted photons from 
the top and from two side surfaces. Hu et al. used a dual-
modality ZKKS-Direct3D molecular imaging system, includ-
ing a scientific liquid-cooled back-illuminated CCD camera 
(Princeton Instruments PIXIS 2048B, Roper Scientific, Tren-
ton, NJ, USA) and a micro-CT system consisting of a micro-
focus X-ray source (Oxford Instruments Series5000 Apogee, 
CA, USA), to localize the implanted radioactive sources by 
Figure 5. Multimodality comparison for the in vivo early detection of small tumor lesions. (a) Sixty-ﬁ ve hours after tumor-cell injection, a photograph shows 
a small tumor lesion (red arrow). (b) BLI conﬁ rms the location of the small tumor lesion. (c) Axial PET shows a false-negative scan. Both (d) without ﬁ ltering and 
(e) with 620 nm ﬁ ltering, CLI (right mouse in each image) shows a false-negative detection (black arrows), but REFI (left mouse) shows true positive detection (red 
arrows). (f) Fluorescence molecular imaging (FMI) of untargeted QD620 shows multiple suspected lesions, and targeted RJ2-DG750 shows overestimation of the 
tumor region. The signal-to-background ratios of both ﬂ uorescent probes are signiﬁ cantly lower than that of REFI. Reproduced from Ref. [80].
Figure 6. (a) An IVIS-200 spectrum imaging system was adapted to image phantom samples/animal subjects (denoted by “S”) pre-administered with 18F-FDG, 
using different optical ﬁ bers (OF) and endoscopes. The subject “S” is placed outside the rectangular ﬁ eld-of-view (FOV) of the imaging system. The input end of the 
OF is placed close to the subject “S”. The output end of the OF faces the CCD camera, which is focused on the output end. (b) A phantom sample (0.2 mL PCR 
tube) containing about 10 µCi of 18F-FDG in 10 µL of phosphate-buffered saline (PBS) was imaged using different OFs and endoscopes with a 1 min exposure 
time. Arrows in all ﬁ gures indicate the distal end of the respective instruments that are within 1 mm of the phantom sample. (c) Detection limits of various optical 
endoscopes and ﬁ bers. Luminescence detected by different ﬁ bers as a function of concentration of 18F-FDG with 1 min exposure time. Reproduced from Ref. [96].
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3D reconstruction; they achieved distance errors in the low 
millimeter range, compared with CLT and SPECT [101]. The 
anesthetized mouse was afﬁ xed to the animal-imaging hold-
er and placed on the rotation stage.
The early CLT reconstruction method adopted the radia-
tive transfer equation (RTE) to describe the photon transport 
problem. The mouse was assumed to be homogeneous and 
all the optical parameters were set by the same value over the 
whole body [100] (Figure 9). Hu et al. introduced the CT data 
as the prior information in order to establish the heteroge-
neous model [101]. As shown in Figure 10, the heterogeneous 
model fuses the CT data and optical data successfully and 
improves the reconstruction accuracy. Spinelli et al. intro-
duced multispectral information to reconstruct the radio-
tracers; this method not only improves the reconstruction 
accuracy but also simplifies the detecting devices [102]. All 
of the methods mentioned above adopt the diffusion equa-
tion in order to approximate the RTE. The diffusion equation 
loses its accuracy in spectrums with short wavelengths, such 
as the blue spectrum. As most emitting photons in Cerenkov 
radiance are in the blue-light spectrum, and the light intensity 
Figure 7. A prototype of a ﬁ ber-based system for endoscopic and laparo-
scopic CLI applications. (a) An optical fiber with a micro-imaging lens was 
coupled to (b) an image-intensified CCD. (c) Mouse 1, bearing C6 glioma 
after tail-vein administration of 37 MBq (1 mCi) of 18F-FDG. The mouse was 
imaged by a commercially available optical IVIS system and by a ﬁ ber-based 
system; tumor tissues are outlined by red lines. Ambient-light images are on 
the left and fused images are on the right. (d) Mouse 1 was imaged by an IVIS 
optical system and by a fiber-based system after surgery to remove tumor 
tissues. Ambient-light images are on the left and fused images are on the right. 
Reproduced from Ref. [97].
Figure 8. (a) Schematic diagram of the Cerenkov optical acquisition setup of 
the system by Li et al. (b) CL measurement from phantom. (c) Experimental 
setup for in vivo measurement. (d) CL measurements from two side views. 
Reproduced from Ref. [100].
Figure 9. Reconstructed CLT images fused with micro-CT images. (a) 
Coronal cross-section showing the bladder and heart and (b) sagittal cross-
section at tumor. (c) & (d) Corresponding fused micro-PET/CT images. 
Reproduced from Ref. [100].
is inversely proportional to the square of the wavelength, the 
diffusion equation is not very appropriate for CLT reconstruc-
317
Medical Instrumentation—Review Research
www.engineering.org.cn  Volume 1 · Issue 3 · September 2015  Engineering
tion. Therefore, a third-order simpliﬁ ed spherical harmonics approximation of RTE 
was employed to model Cerenkov photon propagation by Zhong et al. [103] (Figure 
11). More studies were done to reduce the reconstruction time [104].
surgeons’ eyes and hands. Novel tech-
niques that can extent a surgeon’s vi-
sion and sense of touch are desired. Ex-
isting medical imaging techniques such 
as CT, MRI, and PET can image a tumor 
that is larger than 5 mm in human ap-
plications [105]. However, more sensi-
tive and accurate imaging technologies 
are urgently required. The rising tech-
nology of OMI shows great superiority 
in clinical translations. Fluorescence 
molecular imaging (FMI) technology, a 
branch of OMI, has been applied to sev-
eral clinical surgeries such as ovarian 
cancer [106], early stage esophageal can-
cer diagnosis [107], and sentinel lymph 
node (SLN) detection [108]. There are 
three principal advantages in using FMI 
for complex intraoperative applications: 
① high sensitivity and speciﬁ city in the 
detection of micro lesions; ② real-time 
imaging at the detection area during 
the dissection process; and ③ no radia-
tion or contact with tissues, resulting in 
no inﬂ uence on traditional surgery pro-
cedures. Current studies have already 
proved the high sensitivity and accu-
racy of micro-tumor dissection using 
FMI systems in clinical applications.
To achieve superior sensitivity and 
accuracy in clinical translations and to 
fulfill clinical demands, novel medi-
cal instruments should include three 
important features in addit ion to 
obtaining FDA certification: ① multi-
spectral visualization including white 
light and lesion-specific fluorescence; 
② optimized fluorescence detection 
and sufficient light sources for excita-
tion; ③ convenient manipulation for 
surgeons. Among all other imaging 
challenges, detection depth is the major 
issue for the FMI technique. In order to 
achieve a high signal-to-background 
ratio (SBR) during surgery, the ﬁ rst NIR 
window is commonly used, in which 
light absorption and scattering are rela-
tively low and cannot be seen by the 
naked eye [109]. Many academic and 
commercial systems based on the prin-
ciple of ﬂ uorescence imaging are avail-
able for clinical applications [110–123]. 
Milestone studies, such as precise can-
cer imaging and nerve-damage protec-
tion surgery, have been performed that 
aimed for increasing the precision in 
intraoperative applications [124, 125]. 
Several academic and commercial 
Figure 10. CLT reconstruction of the radioactive source distribution in a mouse with an implanted 
600 µCi Na131I radioactive source. (a) & (b) The 3D renderings of the reconstructed source distribution in (a) 
heterogeneous and (b) homogeneous mouse models. (c) The true source (inside the black circle) in a micro-
CT slice superimposed with the reconstructed source (red triangle) from a sagittal view. Reproduced from 
Ref. [101].
Figure 11. In vivo application of whole-body CLT via ﬁ nite element SP3 approximation with 18F-FDG. 
(a) Schematic diagram of the system setup in radioactive optical imaging. (b) Planar optical signal distribution 
on the body surface, which was around the bladder area with high radiotracer accumulation. (c) The mouse 
was discredited into the tetrahedral mesh as the input of the SP3 model, including 3555 nodes, 38 115 
triangles, and 18 690 tetrahedrons. The reconstructed light source center was inside the bladder with the 
maximum light intensity of 4.4 × 10–12 W.mm–3. (d) Orthogonal slices via the recovered center demonstrated the 
distribution of radiotracer inside the bladder three-dimensionally. Reproduced from Ref. [103].
4 Intraoper ative surgical navigation systems using OMI
Current medical imaging techniques play an important role in the ﬁ eld of preop-
erative diagnosis and post-operative evaluations. However, with regards to intra-
operative imaging technology, the most frequently used imaging modalities were 
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intraoperative FMI systems are currently available for clinical applications (Figure 
12). Depending on the surgical application, these systems can be classiﬁ ed as either 
open-surgery or endoscopic FMI systems. Furthermore, different types of FMI sys-
tems have different advantages due to a focus on different features.
bypass surgery. Recently, the SPY™ 
system has been applied to accurately 
identi fy mastectomy-f lap necrosis 
with the fluorescence imaging agent 
indocyanine green (ICG) in 62 breast-
reconstruction cases during surgery 
[136]. The Photodynamic Eye (PDE™), 
produced by Hamamatsu Photonics, 
is approved by the FDA for clinical ap-
plications including SLN detection in 
breast cancer [137, 138] and liver cancer 
surgery [139]. This handheld imaging 
system emits annular 760 nm LED NIR 
light and uses a single CCD camera to 
detect the reflected fluorescence light. 
As LED light energy is limited, the im-
age quality has great potential for im-
provement for further operation-room 
applications. Another handheld prod-
uct designed by Fluoptics (www.ﬂ uop-
tics.com), named Fluobeam®, has simi-
lar functions as the PDE™ and has been 
used in clinical trials aiming to prove 
its feasibility during surgery. In addi-
tion, ArtemisTM simultaneously shows 
the color image and the fluorescent 
overlay, which provides excellent utility 
for nerve surgery [140, 141]. Nerve pres-
ervation is an important issue during 
most surgery because accidental tran-
section or injury results in significant 
morbidity. NIR window I fluorescent 
light has the potential to provide high 
resolution, high sensitivity, and real-
time avoidance of nerve damage. By 
using a ﬂ uorescent probe, FMI imaging 
can image the nerves in human tissue 
samples. Fluorescence highlighting is 
independent of axonal integrity, sug-
gesting that the probe could facilitate 
the surgical repair of injured nerves 
and help prevent accidental transection 
[142, 143].
4.2 Intraoperative FMI systems for 
endoscopic surgery
Recently, novel f luorescence endo-
scopic and laparoscopic systems were 
designed to realize minimal invasive-
ness and to solve the detection-depth 
problem during surgery [144]. The 
most commercial endoscope systems 
use 400–700 nm visible-light-spectrum 
fluorescence imaging, which is simi-
lar to an ordinary white-light image. 
However, the lack of contrast between 
lesions and normal tissue makes it dif-
ficult for surgeons to decide where to 
Figure 12. Intraoperative FMI systems. (a) The Novadaq SPY™ system. (b) ArtemisTM. (c) Hamamatsu’s 
Photodynamic Eye (PDE™). (d) Fluoptics’ Fluobeam®, Functional intraoperative FMI systems. (e) FLARE™ 
imaging system. (f) Multispectral FMI system from Technische Universität München & Helmholtz Zentrum. 
(g) Surgical navigation system GXMI Navigator from the Institute of Automation, Chinese Academy of 
Sciences [126].
4.1 Intraoperative FMI systems for open surgery
Multispectral intraoperative FMI systems have advantages in image acquiring and 
processing. The FLARE™ system was developed by the Frangioni Laboratory, De-
partment of Radiology, Beth Israel Deaconess Medical Center (www.frangionilab.
org), Harvard Medical School. This system uses dual NIR channels and a white-
light channel to simultaneously collect images. Three CCD cameras are used to col-
lect images in different spectrums: The NIR channel 1 is used to collect light above 
800 nm, the NIR channel 2 is used to collect light between 700–800 nm, and the 
white-light camera is used to collect light between 400–650 nm. The excitation light 
usually used involves two components: halogen for white light at 40 000 lux and 
LEDs for NIR light (4 mW· cm–2 of 670 nm and 11 mW· cm–2 of 760 nm). For the image 
results, different NIR images are pseudocolored with red and green, respectively, 
and merged onto the white-light images. In terms of real-time imaging, the FLARE 
and mini FLARE systems acquire and display images at a rate of 15 fps. This aca-
demic system has been used in several clinical applications such as cancer surgery 
and SLN mapping [115, 127–130]. 
Another multispectral FMI system was developed by Technische Universität 
München and Helmholtz Zentrum (http://www.helmholtz-muenchen.de), and is 
similar to the FLARE system. This system has the advantage of imaging process-
ing that corrects for attenuation from the excitation light, and has been remarkably 
applied to human ovarian cancer surgery [106, 131–134]. Another FMI system was 
developed in the Key Laboratory of Molecular Imaging, Chinese Academy of Sci-
ences (http://www.3dmed.net/), and has the advantage of convenient operation. 
This system also improves the quality of image results by using feature point al-
gorithms in order to ensure rapid and precise imaging fusion for the two cameras 
in the system [135]. The system has been successfully applied in breast cancer SLN 
mapping and liver cancer detection in clinics.
As intraoperative FMI systems aim to assist surgeons in precision surgery, con-
venient designs were considered in many commercial products. The first FDA-
approved FMI product was the SPY™ system developed by Novadaq Technolo-
gies, Inc. (www.novadaq.com). It showed previous application in the ﬁ eld of vessel 
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results showed 82.9% sensitivity and 90.5% speciﬁ city, which 
improved diagnosis and resection thoroughness for bladder 
cancer [149].
In summary, intraoperative surgical navigation systems 
using FMI technology can extend the vision of surgeons, 
enabling them to precisely distinguish lesions from normal 
tissues, and improving surgery sensitivity and accuracy for 
many important biological applications and clinical transla-
tions [150].
5 Perspectives
In the past decade, as more and more researchers and clini-
cians realize the signiﬁ cance of precise medicine and person-
alized cancer-patient treatment based on a fundamental un-
derstanding of cancer biology at the cellular and molecular 
level, enormous strides have been made in the ﬁ eld of in vivo 
OMI and its clinical translations. With this strong motivation, 
many new optical imaging systems, algorithms, agents, and 
reporters have been applied to cancer research, new therapy 
development, and clinical patient care. 
Optical multimodality imaging has transformed the opti-
cal observation of molecular processes and events from a 
crude qualitative planar approach to a quantitative 3D imag-
ing technique. Small-animal whole-body biodistribution, 
the targeting specificity and pharmacokinetics of optical 
molecular probes, and the tumor-cell response to therapeutic 
interventions can all be imaged accurately and dynamically 
in intact host environments. Important biological informa-
tion, such as tumor marker expression, available reporter 
density, and lymph node tumor burden quantiﬁ cation, which 
in the past could only be accessed by analyzing select tissue 
specimens extracted by biopsy or tumor tissue resection, can 
now be analyzed in vivo with unprecedented accuracy and 
sensitivity. 
CLI has provided a new pathway to imaging clinically 
approved radioactive tracers with optical-based technolo-
gies, and exhibits many advantages. This technique has the 
potential to accelerate the speed of clinical translation for 
OMI, as the majority of ﬂ uorescence probes are still limited 
in preclinical applications. The combination of nuclear and 
optical imaging, the two most sensitive imaging modalities, 
Figure 13. Design of endoscopic FMI system. (a) Schematic of the intraoperative imaging system and software pipeline [145]; (b) the clinically applied dual-
channel endoscopic imaging system [146].
dissect. In order to detect early micro-tumor lesions and im-
prove the effects of treatment, several endoscopic techniques 
such as image-enhanced endoscopy, endoscopic microscopy, 
and NIR ﬂ uorescence endoscopy were used to improve diag-
nosis accuracy. Because the NIR FMI technique showed great 
superiority in intraoperative high-SBR imaging, some novel 
NIR endoscopic FMI systems were designed for intraopera-
tive image-guided surgery (Figure 13). 
The challenging problem of how to design the endoscopic 
optical path to simultaneously achieve white-light and NIR 
ﬂ uorescent images has limited most ﬂ uorescence endoscopic 
imaging systems. An NIR fluorescence endoscopic system 
should balance the sensitivity and size of the image detec-
tor, the optical coupling efﬁ ciency, and the excitation energy. 
Glatz et al. used an electron multiplying charge-coupled de-
vice (EMCCD) to increase the detection sensitivity of signiﬁ -
cant contrast between tumors and normal tissues and evalu-
ated their system for the identification of colorectal tumor 
margins [145]. Venugopal et al. reported a unique optical path 
design to simultaneously achieve color and NIR ﬂ uorescence 
images [146]. This prism-based 2-CCD camera endoscopic im-
aging system, which is compatible with two light sources in 
color and in the NIR range, realized one hand operation and 
real-time imaging registration during surgery. Furthermore, 
thoracic SLN mapping in a porcine model validated the feasi-
bility of the system performance. 
For clinical translations, Hide et al. addressed a recurrent 
intracavernous sinus dermoid cyst using an NIR endoscopic 
system in order to confirm the patency of the internal ca-
rotid artery and the cavernous sinus. This NIR endoscope 
was superior for real-time imaging and a high SBR for the 
lesions, and showed great value for successful endonasal 
transsphenoidal surgery [147]. Plante et al. reported a pilot 
study using a novel endoscopic FMI system for SLN map-
ping in cervical and endometrial cancer with ICG [148]. The 
results showed that with the help of an NIR FMI system, SLN 
mapping detection can achieve a very high overall (96%) and 
bilateral (88%) rate. Pan et al. used ﬂ uorescence imaging sys-
tems, confocal endomicroscopy, and blue light cystoscopy in 
fresh surgically removed human bladders with ﬂ uorescently 
labeled CD47 antibody (anti-CD47) as molecular imaging 
agent for accurate diagnosis and image-guided surgery. The 
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may break through the current sensitivity limitation of in 
vivo early-tumor imaging and may provide a way to observe 
tumor progression at a much earlier stage. 
The clinical translation of OMI has been slower than was 
initially hoped for. The reasons behind this slower transla-
tion are complex, but one of the biggest problems involves 
the regulatory hurdles for optical molecular probes. How-
ever, imaging systems and strategies have moved forward 
by exploring the potential clinical applications of FDA-
approved optical imaging agents such as ICG. Intraoperative 
ﬂ uorescent image-guided surgery has become well-accepted 
in clinical trials, with promising tumor-resection accuracy in 
tumor-margin deﬁ nition and superb sensitivity in tiny tumor 
foci or residual detection. The outdated perception of lower 
market proﬁ t margins for OMI than for therapeutic drugs is 
gradually changing. 
With recent advances in OMI technologies, we believe that 
more and more unveriﬁ ed biomedical hypotheses can be in-
vestigated using more powerful imaging strategies, and sig-
niﬁ cant new discoveries in oncology can be achieved through 
imaging observation. The more accurate and sensitive imag-
ing studies performed using OMI have enabled researchers 
to obtain a deeper and better understanding of molecular 
processes and evens of cancer—an understanding that is 
likely to motivate even faster development of OMI in the next 
decade. The clinical translation of these novel imaging tech-
nologies will continue and accelerate. Applying these new 
optical imaging technologies to human healthcare will lead 
to a fundamental improvement in diagnostic and therapeutic 
cancer interventions. In the era of molecular imaging, optical 
technologies hold great promise to facilitate the development 
of highly accurate and sensitive cancer diagnoses as well as 
personalized patient treatment—one of the ultimate goals of 
precision medicine.
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